Ahmad Ghorab
0000-0003-3429-2737
Mayo Clinic
23 papers found
Refreshing results…
Heyde’s syndrome: a challenging case of severe aortic stenosis and gastrointestinal bleeding
Clinicopathologic Features and Survival Outcomes of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) of the Urothelial Organs (Urologic MALT Lymphoma): The Mayo Clinic Experience (2013-2022)
Experience with Gray Zone Lymphoma (GZL) at Mayo Clinic: A Review of Clinical Characteristics and Treatment Outcomes
AML-497 Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes
Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
MDS-353 Clinical Outcome of Myelodysplastic Syndrome Progressing on Hypomethylating Agents With Evolving Frontline Therapies: Continued Challenges and Unmet Needs
Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients
Comprehensive Analysis of Prognostic Factors, Outcomes and Mutation Profile in Patients With Aggressive Histology (Blastoid/Pleomorphic) or Transformed Mantle Cell Lymphoma
Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib
Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes.
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation.
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients
Pattern of mutational changes in patients with chronic phase CML who are treated with frontline TKI and transform to blast phase CML
Comparative risk assessment of imatinib, nilotinib and dasatinib in randomized controlled trials: a meta-analysis
Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes
Missing publications? Search for publications with a matching author name.